Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Sponsors and Collaborators
Nymox Corporation

Contact
There will be multiple sites for this clinical trial. For further information, contact Nymox at 800-936-9669 or info@nymox.com

ClinicalTrials.gov Identifier
NCT01620515

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters